ZeroOCD: Learn to Overcome Contamination OCD With Your Smartphone
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: ZeroOCD, Videoconferencing CBT.
- Who it may be relevant to
- Registry conditions: Obsessive Compulsive Disorder (OCD). Basic parameters: 18 years — 64 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Belgium, Netherlands, Sweden, Switzerland
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
ZeroOCD: Learn to Overcome Contamination OCD With Your Smartphone: An Augmented Reality Cognitive Behavioral Therapy App for Obsessive-Compulsive Disorder: Randomized Controlled Trial
Overview
This study is a three-arm randomized controlled trial designed to evaluate the efficacy of a smartphone-based augmented reality (AR) cognitive behavioral therapy (CBT) app, called ZeroOCD, for individuals with elevated contamination-related obsessive-compulsive disorder (OCD) symptoms. The AR-CBT app will be compared to both an active control condition (manualized CBT via videoconferencing) and a waitlist control group.
Detailed description
Obsessive-compulsive disorder (OCD) is a prevalent and disabling condition, with contamination fears being one of its most common presentations. While Cognitive-Behavioral Therapy (CBT) with Exposure and Response Prevention (ERP) is a first-line treatment, many individuals face barriers to accessing it, such as cost, stigma, and availability of therapists. This multicenter trial, conducted in the Netherlands, Belgium, Sweden, and Switzerland, will recruit a total of 189 individuals experiencing contamination-related obsessive-compulsive symptoms. Participants will be randomized to one of three study conditions (allocation ratio 2:2:1): The first group (n = 75) receives access to ZeroOCD, an augmented reality (AR) based smartphone application, which provides CBT and ERP for contamination fears, along with three therapist support sessions via videoconferencing. The second group (n = 75) receives weekly CBT for OCD via videoconferencing (nine sessions in total). The third group is a waitlist control group (n = 39), who will receive access to the smartphone application with minimal therapist support on request after 10 weeks in the study. The study aims to evaluate the effectiveness of the ZeroOCD intervention compared to both a waitlist control and videoconferencing CBT, and to assess cost-effectiveness and usability. Assessments are conducted at baseline, 10 weeks post-randomization, and at 6-month follow-up for the intervention groups. Participants in the waitlist group complete assessments at baseline, 10 weeks post-randomization, and receive access to the ZeroOCD intervention 10 weeks after randomization. Further, the waitlist group will complete an assessment 20 weeks post-randomization. The study is a multicenter trial involving participants in Switzerland, the Netherlands, Belgium, and Sweden.
Interventions
- Behavioral ZeroOCD
The ZeroOCD app contains the following components: psychoeducation, detecting obsessive thoughts, coping with obsessions, goal setting, fear curve explanation, exposure with AR, re-exposure with AR, exposure hierarchy, exposure in real-life, re-exposure in real life and relapse prevention - Behavioral Videoconferencing CBT
Videoconferencing CBT contains the following chapters: psychoeducation, detecting obsessive thoughts, coping with obsessions, goal setting, fear curve explanation, exposure hierarchy, exposure in real-life, re-exposure in real life and relapse prevention
Primary outcome measures
- OCD Symptoms (Interview) [Time frame: At baseline, At 10 weeks, At 20 weeks (only WL condition) At 24 weeks]
Secondary outcome measures (12)
- OCD symptoms (Self-report) [Time frame: At baseline, During treatment (every week) At 10 weeks, At 24 weeks]
- Fear of Contamination [Time frame: At baseline, At 10 weeks, At 20 weeks (only WL condition) At 24 weeks]
- Depression [Time frame: At baseline, At 10 weeks, At 24 weeks]
- Anxiety [Time frame: At baseline, At 10 weeks, At 24 weeks]
- Current Distress/Disgust [Time frame: up to ten weeks]
- Social Functioning [Time frame: At baseline, At 10 weeks, At 24 weeks]
- Health Related Quality of Life [Time frame: At baseline, At 10 weeks, At 24 weeks]
- Societal Costs of a Treatment [Time frame: At baseline, At 10 weeks, At 24 weeks]
- Usability [Time frame: At 10 weeks (only ZeroOCD condition), At 20 weeks (only WL condition)]
- Treatment Satisfaction [Time frame: At 10 weeks (only intervention groups)]
- Realism of AR-Environment [Time frame: At 10 weeks (only ZeroOCD condition)]
- Negative Effects of Treatment [Time frame: At 10 weeks (only ZeroOCD and CBT condition), at 20 weeks (only waitlist condition)]
Eligibility criteria
Inclusion criteria
- • OCD symptoms, mean score > 7 on the Yale Brown Obsessive Compulsive Scale (Y-BOCS)
- Fear of contamination OCD symptoms, mean score > 6 on the Padua Inventory contamination fear subscale (PI)
- Having access to a compatible smartphone
- Having an internet connection
- Proficiency in one of the countries' languages (i.e., Dutch/ Flemish, German, or Swedish)
- Willing to participate in the research study and provide informed consent
Exclusion criteria
- • Having been diagnosed with bipolar or psychotic disorder (self-report)
- Severe depressive symptoms (Patient Health Questionnaire, PHQ-9, score > 20)
- Reporting suicidality (PHQ-9, item 9 > 2 points at screening)
- Fear of contamination due to disorder other than OCD (clinical judgment based on results from the Yale Brown Obsessive Compulsive Scale, Y-BOCS, Generalized Anxiety Disorder-7 items, GAD-7, Short Health Anxiety Inventory, SHAI)
- Parallel psychological treatment
- Non-stable dosage of psychoactive medication during the last three months or planned changes during the study period.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Open label
- Primary purpose
- Treatment
Study locations
Belgium · 1 center
- Thomas More Mechelen — Mechelen
Netherlands · 1 center
- Vrije Universiteit Amsterdam — Amsterdam
Sweden · 1 center
- Stockholm University — Stockholm
Switzerland · 1 center
- UBERN — Bern
Identifiers
NCT: NCT07194473 · ZeroOCD/FP-1478